Demographic characteristics and cardiovascular risk factors of myocardial infarction (MI) cases and matched controls
| MI cases (n=2277) | Controls (n=4849) | aOR (95% CI) | |
|---|---|---|---|
| Age, years (mean±SD) | 59.3±11.6 | 59.7±12.3 | NA |
| Sex, male | 76.4 | 67.8 | NA |
| Hypertension | 56.3 | 54.5 | NA |
| Body Mass Index (kg/m2) | |||
| ≤24 (normal) | 36.6 | 40.3 | 1 |
| 25–29 (overweight) | 44.5 | 42.8 | 1.05 (0.93 to 1.18) |
| ≥30 (obese) | 18.9 | 16.9 | 1.13 (0.97 to 1.32) |
| Hyperlipidaemia* | 39.9 | 38.1 | 1.16 (1.03 to 1.32) |
| Ever smoker | 72.7 | 56.8 | 1.91 (1.69 to 2.16) |
| Regular alcohol consumption$† | 48.4 | 47.0 | 0.88 (0.79 to 0.99) |
| >30 min physical activity per day | 21.2 | 29.4 | 0.63 (0.55 to 0.71) |
| Diabetes | 14.5 | 12.4 | 1.17 (1.00 to 1.37) |
| Use of drug for vascular disease or risk factor‡ | 61.8 | 66.8 | 0.77 (0.68 to 0.87) |
| NSAIDs in previous 2 months | 21.1 | 21.7 | 1.00 (0.88 to 1.14) |
Data are % unless indicated.
Adjusted ORs (aORs) and 95% CIs from conditional multivariate logistic regression model including Body Mass Index, smoking, alcohol consumption, physical activity, diabetes, previous use (yes, no) of any cardiovascular drug, intake of non-steroidal anti-inflammatory drugs (NSAIDs; including acetylsalicylic acid) in the previous 2 months.
*Hyperlipidemia is defined by ‘reported by the physician’ or a lipid-lowering drug use.
$†Every day or several times per week.
‡Blood pressure lowering drug, lipid-lowering drug.